

ACADIA.020A



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andersson, et al.
Appl. No.	: 10/601,070
Filed	: June 20, 2003
For	: N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS
Examiner	: Aulakh, C.
Group Art Unit	: 1625

DECLARATION OF DR. CARL-MAGNUS ANDERSSON
UNDER 37 C.F.R. 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, Carl-Magnus Andersson, Ph.D., declare and state:

1. The purpose of this declaration is to establish my invention of subject matter in U.S. Patent 6,756,393.

2. I am an inventor of the invention of Claims 1-7, 9-14, 17, 18, and 20-35 of the above-identified application and am familiar with the specification, claims, and prosecution history thereof. These claims are directed to compounds of Formula I, which modulate the activity of monoamine receptors.

3. I have read the Office Action mailed November 4, 2004, and understand that Claims 1-7, 9-14, 17, 18, and 20-35 have been rejected under 35 U.S.C. § 102(e) as being anticipated by several compounds disclosed in U.S. Patent No. 6,756,393 ("the '393 patent") to Andersson et al.

4. I conceived and invented several of the compounds disclosed in Columns 16-19 of the '393 patent. The compounds of the '393 patent that I invented include:

Appl. No. : 10/601,070
Filed : June 20, 2003

- 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-((2-chloro-5-thienyl)methyl)piperidin-4-yl]acetamide;
- 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(2-(imidazolidinon-1-yl)ethyl)piperidin-4-yl]acetamide;
- 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-{1-[2-(2,4(1H,3H)quinazolinedion-3-yl)ethyl]piperidin-4-yl}acetamide;
- 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-{1-[2-(1,3-dioxolan-2-yl)ethyl]piperidin-4-yl}acetamide;
- 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-{1-[2-(3-indolyl)ethyl]piperidin-4-yl}acetamide;
- 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-{1-[3-(1,2,4-triazol-1-yl)propyl]piperidin-4-yl}acetamide;
- 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(5-benzofurazanylmethyl)piperidin-4-yl]acetamide;
- 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(5-chlorobenzo[b]thien-3-ylmethyl)piperidin-4-yl]acetamide; and
- 2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(5-phenyl-1,2,4-oxadiazol-3-ylmethyl)piperidin-4-yl]acetamide.

These compounds are disclosed in the '393 patent at Column 18, lines 21-43.

5. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity and/or enforceability of the application and/or any patent issuing therefrom.

Dated: 2/20/05

By: 
Carl-Magnus Andersson, Ph.D.